Answers are grounded in this paper and cite their sources.
This paper analyses manufacturers’ dual obligations under the European Union (EU) AI Act and Medical Device Regulation (MDR). It shows that divergent classification rules generate parallel high-risk pathways, that post-market surveillance regimes differ in scope and mechanics, and that human oversight duties remain undefined in audit-ready, clinical terms. Friction is most acute in continuously learning models, where the MDR’s static clinical evaluation assumptions collide with the AI Act’s demand for ongoing validation. These conflicts increase compliance costs, delay market access and favour incumbents. The paper recommends procedural harmonisation: joint guidance, integrated conformity workstreams, explicit thresholds for model updates, auditable oversight controls and interoperable monitoring systems. It concludes that coordinated supervisory practice and compliance-by-design governance are the most workable means of aligning device safety with artificial intelligence (AI)-specific risk management. This article is also included in The Business & Management Collection which can be accessed at https://hstalks.com/business/.
No takes yet. Share an insight, caveat, or question.
Musch et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: